Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
Future directions in adjuvant therapy for rectal cancer.
A. B. Benson
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
4
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Future directions in adjuvant therapy for rectal cancer.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Radiation
100%
Overall Survival
50%
Lymph Node
50%
Recurrence Free Survival
33%
Capecitabine
33%
Rectum Cancer
33%
Levamisole
33%
Patient
33%
Neoplasm
16%
Development
16%
Disease Free Survival
16%
Survival Rate
16%
Fluorouracil
16%
Combination Therapy
16%
High Risk Population
16%
Specimen
16%
Irinotecan
16%
Intravenous Drug Administration
16%
Recurrence Risk
16%
Malignant Neoplasm
16%
Evaluation Study
16%
Oxaliplatin
16%
Chemotherapeutic Agent
16%
Molecular Marker
16%
Drug
16%
Folinic Acid
16%
Assessment
16%
Laboratory
16%
Therapeutic Procedure
16%
Breast
16%
Adjuvant Therapy
16%
INIS
risks
66%
cancer
50%
radiations
50%
lymph nodes
50%
surgery
33%
patients
33%
therapy
33%
rectum
33%
evaluation
16%
laboratories
16%
design
16%
drugs
16%
tumors
16%
assessments
16%
diseases
16%
comparative evaluations
16%
failures
16%
infusion
16%
breasts
16%
chemotherapy
16%
fluorouracils
16%
leucovorin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
50%
Capecitabine
33%
Recurrence Free Survival
33%
Rectum Cancer
33%
Levamisole
33%
Chemotherapy
33%
Disease Free Survival
16%
Survival Rate
16%
Fluorouracil
16%
Neoplasm
16%
Irinotecan
16%
Malignant Neoplasm
16%
Molecular Marker
16%
Folinic Acid
16%
Recurrence Risk
16%
Oxaliplatin
16%
Drug
16%